74029-45-1

Upstream product

• 109-72-8 n-butyllithium 
• 32664-14-5 2-(4-bromophenyl)-4,4-dimethyl-2-oxazoline 
• 74029-48-4 (4-(4,5-dihydro-4,4-dimethyloxazol-2-yl)phenyl)methanol 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 74012-18-3 2-(4-[1,3]dioxolan-2-yl-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 74012-17-2 2-(4-dimethoxymethyl-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 74012-35-4 4,4-dimethyl-2-[4-(4,4,6c-trimethyl-[1,3]dioxan-2r-yl)-phenyl]-4,5-dihydro-oxazole 
• 74012-32-1 4,4-dimethyl-2-[4-(cis-4-methyl-[1,3]dioxan-2-yl)-phenyl]-4,5-dihydro-oxazole 
• 74012-20-7 4,4-dimethyl-2-[4-(5-phenyl-[1,3]dioxan-2-yl)-phenyl]-4,5-dihydro-oxazole 
• 143976-72-1 4,4-dimethyl-2-[4-(trans-5-phenyl-[1,3]dioxan-2-yl)-phenyl]-4,5-dihydro-oxazole 
• 74012-19-4 2-(4-[1,3]dioxan-2-yl-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 74012-33-2 2-[4-(4c,6c-dimethyl-[1,3]dioxan-2r-yl)-phenyl]-4,4-dimethyl-4,5-dihydro-oxazole 
• 74012-33-2 2-[4-(4r,6t-dimethyl-[1,3]dioxan-2-yl)-phenyl]-4,4-dimethyl-4,5-dihydro-oxazole 
• 74029-48-4 (4-(4,5-dihydro-4,4-dimethyloxazol-2-yl)phenyl)methanol 
• 356072-65-6 1-[4-(4,4-Dimethyloxazolin-2-yl)phenyl]-1-(2-methoxyphenyl)methyl alcohol 
• 74029-49-5 2-(4-methoxymethyl-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 74029-46-2 {2-[4-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-phenyl]-[1,3]dioxolan-2-yl}-phenyl-methanone 
• 74012-24-1 1-{2-[4-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-phenyl]-[1,3]dioxolan-2-yl}-2-methyl-propan-1-ol 

Relevant academic research and scientific papers

Anti-inflammatory piperazinyl-benzyl-tetrazole derivatives and intermediates thereof

This invention relates to tetrazoles and their pharmaceutically acceptable salts which are selective agonists for the delta opioid receptor, particularly useful in the treatment of inflammatory diseases such as arthritis, psoriasis, asthma, inflammatory bowel disease, disorders or respiratory function, gastrointestinal disorders such as functional bowel disease and functional GI disorders, of formula (I) wherein R1is H, C2-C6alkanoyl, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)-(C1-C4alkyl), (C1-C4alkoxy)-(C1-C4alkyl), carboxy-(C1-C4alkyl), aryl-(C1-C4alkyl) or heteroaryl-(C1-C4alkyl); R2and R3are each independently H or C1-C4alkyl; R4is selected from (i) H, (ii) a group of the formula R6—(CH2)m—Z—(CH2)n—, where m is 0, 1, 2 or 3, n is 1, 2 or 3, Z is a direct link or O, and R6is —CO2H or —CO2(C1-C4alkyl), and (iii) a group of formula (a) where R7is H or C1-C4alkyl; and R5is hydroxy, C1-C4alkoxy or —NHSO2(C1-C4alkyl); with the proviso that when Z is O, m is 1, 2 or 3 and n is 2 or 3.

Phenoxyalkylamine derivatives useful as opioid receptor agonists

A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH2 and the like, “n” represents 0 to 2, R1 represents a hydrogen atom, a halogen atom and the like, R2, R3, and R7 to R14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R5 represents a hydrogen atom, a halogen atom and the like, R6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R5 and R6, R7 and R8, R9 and R10, or R11 and R12 may bind to each other to form a cyclic structure.